These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 23295078)

  • 21. Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas.
    Hensley ML
    Curr Opin Oncol; 2010 Jul; 22(4):356-61. PubMed ID: 20520541
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm.
    Arend RC; Toboni MD; Montgomery AM; Burger RA; Olawaiye AB; Monk BJ; Herzog TJ
    Oncologist; 2018 Dec; 23(12):1533-1545. PubMed ID: 30139839
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An increasing role for trabectedin in gynecological cancers: efficacy in uterine sarcomas.
    Ray-Coquard I
    Int J Gynecol Cancer; 2011 May; 21 Suppl 1():S3-5. PubMed ID: 21540667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase II study of gemcitabine and docetaxel combination in relapsed metastatic or unresectable locally advanced synovial sarcoma.
    Tansir G; Rastogi S; Kumar A; Barwad A; Mridha AR; Dhamija E; Shamim SA; Bhatnagar S; Bhoriwal S
    BMC Cancer; 2023 Jul; 23(1):639. PubMed ID: 37422615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of metastatic uterine leiomyosarcoma with cisplatin, pirarubicin, and ifosfamide.
    Hirota Y; Miyamura K; Hayata T; Miyakawa I
    Gynecol Obstet Invest; 1997; 44(1):70-2. PubMed ID: 9251960
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation.
    Ricci S; Stone RL; Fader AN
    Gynecol Oncol; 2017 Apr; 145(1):208-216. PubMed ID: 28209496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma?
    Ricci S; Giuntoli RL; Eisenhauer E; Lopez MA; Krill L; Tanner EJ; Gehrig PA; Havrilesky LJ; Secord AA; Levinson K; Frasure H; Celano P; Fader AN
    Gynecol Oncol; 2013 Dec; 131(3):629-33. PubMed ID: 24016408
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery.
    Pautier P; Floquet A; Chevreau C; Penel N; Guillemet C; Delcambre C; Cupissol D; Selle F; Isambert N; Piperno-Neumann S; Saada-Bouzid E; Bertucci F; Bompas E; Alexandre J; Collard O; Lebrun-Ly V; Soulier P; Toulmonde M; Le Cesne A; Lacas B; Duffaud F;
    ESMO Open; 2021 Aug; 6(4):100209. PubMed ID: 34325109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stable disease in a patient with metastatic leiomyosarcoma treated with trabectedin.
    Tavella K; Villanucci A; Vannini L; Lavacchi D; Montelatici S; Amunni G; Mazzei T
    Anticancer Drugs; 2017 Apr; 28(4):465-468. PubMed ID: 28181940
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of bevacizumab in uterine leiomyosarcoma.
    Bogani G; Ditto A; Martinelli F; Signorelli M; Chiappa V; Fonatella C; Sanfilippo R; Leone Roberti Maggiore U; Ferrero S; Lorusso D; Raspagliesi F
    Crit Rev Oncol Hematol; 2018 Jun; 126():45-51. PubMed ID: 29759566
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic chemotherapy for inoperable, locally advanced, recurrent or metastatic uterine leiomyosarcoma.
    Martin-Liberal J; Benson C
    Clin Oncol (R Coll Radiol); 2013 Jun; 25(6):343-5. PubMed ID: 23507441
    [No Abstract]   [Full Text] [Related]  

  • 32. A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study.
    Monk BJ; Blessing JA; Street DG; Muller CY; Burke JJ; Hensley ML
    Gynecol Oncol; 2012 Jan; 124(1):48-52. PubMed ID: 21996263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and toxicities of doxorubicin plus ifosfamide in the second-line treatment of uterine leiomyosarcoma.
    Niu SY; Sun L; Hsu ST; Hwang SF; Liu CK; Shih YH; Lu TF; Chen YF; Lai LC; Chang PL; Lu CH
    Front Oncol; 2023; 13():1282596. PubMed ID: 38090488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic review of systemic therapy for advanced or recurrent endometrial cancer.
    Carey MS; Gawlik C; Fung-Kee-Fung M; Chambers A; Oliver T;
    Gynecol Oncol; 2006 Apr; 101(1):158-67. PubMed ID: 16434086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
    Hensley ML; Sill MW; Scribner DR; Brown J; Debernardo RL; Hartenbach EM; McCourt CK; Bosscher JR; Gehrig PA
    Gynecol Oncol; 2009 Dec; 115(3):460-5. PubMed ID: 19811811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gemcitabine and Docetaxel Compared With Observation, Radiation, or Other Chemotherapy Regimens as Adjuvant Treatment for Stage I-to-IV Uterine Leiomyosarcoma.
    Roque DR; Taylor KN; Palisoul M; Wysham WZ; Milam B; Robison K; Gehrig PA; Raker C; Kim KH
    Int J Gynecol Cancer; 2016 Mar; 26(3):505-11. PubMed ID: 26807641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of advanced uterine leiomyosarcoma.
    Hyman DM; Grisham RN; Hensley ML
    Curr Opin Oncol; 2014 Jul; 26(4):422-7. PubMed ID: 24840518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
    Sutton G; Blessing J; Hanjani P; Kramer P;
    Gynecol Oncol; 2005 Mar; 96(3):749-52. PubMed ID: 15721421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Docetaxel and gemcitabine in the treatment of soft tissue sarcoma - a single-center experience.
    Ebeling P; Eisele L; Schuett P; Bauer S; Schuette J; Moritz T; Seeber S; Flasshove M
    Onkologie; 2008 Feb; 31(1-2):11-6. PubMed ID: 18268394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study).
    Pautier P; Penel N; Ray-Coquard I; Italiano A; Bompas E; Delcambre C; Bay JO; Bertucci F; Delaye J; Chevreau C; Cupissol D; Bozec L; Eymard JC; Saada E; Isambert N; Guillemet C; Rios M; Piperno-Neumann S; Chenuc G; Duffaud F
    Eur J Cancer; 2020 Jan; 125():31-37. PubMed ID: 31835236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.